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Abstract 
Sphingolipids are essential components of eukaryotic cell membranes, particularly 
the plasma membrane, and are involved in a diverse array of signal transduction 
pathways. Mammals produce sphingomyelin (SM) as the primary complex 
sphingolipid via the well characterised SM synthase. In contrast yeast, plants and 
some protozoa utilise an evolutionarily related inositol phosphorylceramide (IPC) 
synthase to synthesize IPC. This activity has no mammalian equivalent and IPC 
synthase has been proposed as a target for anti-fungals and anti-protozoals. However, 
detailed knowledge of the sphingolipid biosynthetic pathway of the apicomplexan 
protozoan parasites was lacking. In this study bioinformatic analyses indicated a 
single copy orthologue of the putative SM synthase from the apicomplexan 
Plasmodium falciparum (the causative agent of malaria) was a bona fide sphingolipid 
synthase in the related model parasite, Toxoplasma gondii (TgSLS). Subsequently, 
TgSLS was indicated, by complementation of a mutant cell line, to be a functional 
orthologue of the yeast IPC synthase (AUR1p), demonstrating resistance to the well 
characterised AUR1p inhibitor aureobasidin A. In vitro, recombinant TgSLS exhibited 
IPC synthase activity and, for the first time, the presence of IPC was demonstrated in 
T. gondii lipid extracts by mass spectrometry. Furthermore, host sphingolipid 
biosynthesis was indicated to influence, but be non-essential for, T. gondii 
proliferation, suggesting that whilst scavenging does take place de novo sphingolipid 
synthesis may be important for parasitism. 
 
Keywords: Toxoplasma, sphingolipid, inositol phosphorylceramide, synthase host 
interaction 
 
 
The abbreviations used are: PI – Phosphatidylinositol; PC – Phosphatidylcholine; PE – Phosphatidylethanolamine; IPC – 
Inositol phosphorylceramide; SM – Sphingomyelin; CPE – Ceramide phosphorylethanolamine; NBD-C6-ceramide – N-[6-[(7-
nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-erythro-sphingosine; CHAPS – 3-[(3-cholamidopropyl) dimethylammonio]-1-
propanesulfonate; TgSLS – Toxoplasma gondii sphingolipid synthase; MEF – Mouse Embryonic Fibroblasts 
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1. Introduction 
 
Toxoplasma gondii is an obligate, intracellular protozoan parasite, which is able to invade 
and colonize a wide variety of nucleated vertebrate cells. It is a member of the Apicomplexa, 
a diverse phylum including important pathogens of humans and domestic animals such as 
Plasmodium (the causative agent of malaria), Cryptosporidium (diarrhoea), Eimeria 
(coccidiosis in poultry) and Theileria (East Coast Fever in cattle). Toxoplasma has emerged 
as an opportunistic pathogen and toxoplasmosis is an important disease in the 
immunocompromised, particularly AIDS patients, those receiving anti-cancer chemotherapy 
and organ transplant recipients [1]. Toxoplasma infection in utero is also a significant cause 
of congenital defects in humans [1] and spontaneous abortion in economically important 
domestic animals [2]. 
Sphingolipids are amphipathic lipids comprising sphingosine as the basic building unit. More 
complex sphingolipids consist of a sphingosine backbone N-acylated with a long-chain fatty 
acid (i.e. ceramide) and substituted with a head group moiety (e.g. sphingomyelin, 
glucosylceramide and ceramide-1-phosphate) [3]. Ceramide is a sphingolipid that functions 
as a secondary messenger in ubiquitous, evolutionarily conserved, signalling mechanisms 
[4]. Complex sphingolipids are major components of the outer leaflet of eukaryotic plasma 
membranes that are thought to be involved, together with sterols, in the formation of micro-
domains known as lipid rafts. These rafts have been proposed to function in a diverse array 
of processes from the polarised trafficking of lipid-modified proteins, to the assembly and 
activation of signal transduction complexes [5]. In the apicomplexan Plasmodium species, 
sphingolipid-enriched lipid rafts have been implicated in the interaction of the parasite with 
the host erythrocyte through the trafficking of both host and parasite 
glycosylphosphatidylinositol (GPI) anchored proteins [6]. In addition, it has been 
demonstrated, by the incorporation of tritiated serine, that both P. falciparum and T. gondii 
synthesize sphingolipids de novo [7, 8]. Like mammals, P. falciparum synthesizes the 
complex phosphosphingolipid sphingomyelin (SM) [9-11] and an orthologue of the 
mammalian enzyme, SM synthase, has been identified from the genome database [12]. T. 
gondii has also been indicated to synthesize SM, although at relatively low levels compared 
to glycosphingolipids [8], and the presence of this species has subsequently been confirmed 
using mass spectrometry [13]. However, the enzyme responsible for any SM synthase 
activity has remained unidentified in T. gondii, and uncharacterised in any apicomplexan. 
Furthermore, it has also been reported that the parasites harbour relatively high quantities of 
ceramide phosphorylethanolamine (CPE), a non-abundant species in mammalian cells [13]. 
In addition, the synthesis of the non-mammalian phosphosphingolipid, inositol 
phosphorylceramide (IPC), has also been reported in T. gondii [14]. Importantly, the 
biosynthetic enzyme, IPC synthase, has been validated as a drug target in both the fungi and 
the kinetoplastid protozoa [15-18], and its inhibition by the anti-fungal aureobasidin A has 
been proposed in T. gondii [14]. 
Notably, in addition to de novo synthesis, intracellular parasites such as T. gondii may 
scavenge sphingolipids or their precursors from the host cell [19]. Indeed it has been 
suggested that the CPE (and SM) found in intracellular tachyzoites forms may result from the 
concentration of non-abundant host-derived lipid [13]. Within the host cell T. gondii resides 
within a specialized parasitophorous vacuole (PV) formed immediately after invasion and 
delineated by the PV membrane (PVM) [20]. Although the PV resists fusion with host 
organelles it does demonstrate an intimate, high affinity association with the ER and 
mitochondrion [21], the latter facilitating the scavenging of host lipoic acid [22]. Furthermore, 
recent work has indicated that host-derived lipid is the primary contributor to the intravacuolar 
network that fills the lumen of the PV [23]. Toxoplasma scavenges a variety of fatty acids and 
lipids from the host, including phospholipids and cholesterol, some of which are further 
metabolised by the parasite [24, 25]. The mechanism of lipid scavenging is unclear, although 
current data argue against passive diffusion, acquisition on invasion [25] and (at least in the 
case of cholesterol) vesicular trafficking [24]. It has been proposed that the transport of 
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cholesterol to the PV could be mediated via a protein carrier [24], and the possibility of direct 
inter-organelle transfer of lipids between the closely associated PVM and host ER and 
mitochondrial membranes has been evoked [22, 25]. The balance between de novo 
synthesized and scavenged lipid is unclear, however when host phosphatidylcholine (PC) 
levels are restricted it is likely that the parasites scavenge choline and synthesize PC de 
novo [25]. 
To begin to understand the role of both de novo synthesis and scavenging of sphingolipid for 
T. gondii, we aimed to begin characterization of the little understood parasite biosynthetic 
pathway and investigate the requirement, if any, for host sphingolipid. To these ends we 
herein report the identification and functional characterization of a key enzyme in T. gondii 
sphingolipid synthesis that may represent a novel drug target and, in addition, show the 
delineation of the role of host biosynthesis in parasite proliferation. 
 
 
2. Materials and methods 
 
2.1. Selection, sequence analyses and cloning of candidate sphingolipid synthase 
The T. gondii genome database (www.toxodb.org) was interrogated (Gish, 1996-2001) 
http://blast.wustl.edu) with the two candidate sphingolipid synthase coding sequences 
previously identified from the genome database of the malaria parasite P. falciparum 
(plasmodb.org) [12]. A single sequence orthologue was identified, TgSLS accession number 
TGME49_046490, corresponding to the entry previously identified [13]. Sequence 
alignments were made using ClustalW [26] and phylogenetic analyses performed on the 
edited alignments using Maximum Parsimony, Protein Distance (PHYLIP Phylogeny 
Inference Package, version 3.5c) and Maximum Likelihood [27]. The candidate TgSLS open 
reading frame was amplified from genomic T. gondii DNA using Pfu polymerase (Promega) 
and the primer pair 5’TgSLSEcoRI (cgcgaattcATGCCCAGAACAGAGATG) and 
3’TgSLS*HindIII (cccaagcttTTAGAGTCCCTCGATGGCGCGAACGAT). Cloning sites shown 
in lower case, with coding sequence in upper case. The product was purified, digested and 
cloned into the yeast expression vector pRS426MET25 creating pRS426 TgSLS. 
 
2.2. Functional complementation of auxotrophic yeast AUR1 mutant  
pRS426 TgSLS, together with pRS426 AUR1 and empty vector, were used to transform the 
YPH499–HIS–GAL–AUR1 S. cerevisiae strain [28]. Transformants were selected on non-
permissive SD-HIS-URA medium (0.17% Bacto yeast nitrogen base, 0.5% ammonium 
sulphate and 2% dextrose) or permissive SGR-HIS-URA medium (0.17% Bacto yeast 
nitrogen base, 0.5% ammonium sulphate, 4% galactose and 2% raffinose) containing the 
appropriate nutritional supplements at 30°C. 
 
2.3. In vitro assay of TgSLS activity  
Microsomal membranes from exponentially growing YPH499–HIS–GAL–AUR1 pRS426 
TgSLS or pRS426 AUR1 in SD-HIS-URA were prepared and the isolated membrane fraction 
re-suspended in storage buffer (50 mM Tris/HCl pH 7.4, 20% (v/v) glycerol, 5 mM MgCl2) 
with Complete® EDTA-free Protease Inhibitor Cocktail (Roche Applied Science) at a protein 
concentration of 10mg/ml as described previously [18]. Microsomal membranes were 
subsequently washed in 40mM CHAPS (4 °C, 60 minutes), isolated by centrifugation 
(150000g, 4°C and 100 minutes), re-suspended in storage buffer at 10 mg/ml and stored at 
−80 °C until use. The assay mix contained 1mM donor substrate (bovine liver PI, PC or PE, 
Avanti Polar Lipids), 20µg microsome prep, 100mM Tris HCl, 10mM EDTA, 6mg/ml BSA and 
5µM NBD C6-ceramide [19]. Following incubation at 30 °C for 60 minutes the reaction was 
quenched by the addition of 150µl of Chloroform:Methanol:Water (10:10:3) and lipids 
separated and analyzed as above. For inhibition experiments the reaction mix was pre-
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incubated for 30 minutes with appropriate quantities of aureobasidin A (Takara Bio Inc.) 
before the addition of NBD C6-ceramide.  
 
2.4. Agar diffusion assay  
YPH499-HIS-GAL-AUR1 complemented with TgSLS or AUR1 were assayed for 
susceptibility to aureobasidin A and myriocin (Sigma) as previously described [28]. Briefly, 
2.4 OD600 units of logarithmically dividing cells were embedded in 15ml of SD-HIS-URA with 
0.8% agarose on 100mm2 square Petri dishes (Sarstedt). Inhibitors were applied in DMSO at 
the concentrations indicated and the dishes incubated at 30 °C.  
 
2.5. Mass spectrometry of Toxoplasma gondii inositol phosphorylceramide 
T. gondii (strain RH) were harvested from infected MEF host cells by passage through a 26-
gauge needle and purified by separation on Sephadex-G25 columns (Amersham). Following 
PBS wash, the parasites were transferred to glass vials. Sphingolipid extracts were prepared 
as described [29] and analyzed. The liquid chromatography-mass spectrometer consisted of 
a Waters Aquity UPLC system connected to a Waters LCT Premier orthogonal accelerated 
time of flight mass spectrometer (Waters, Millford, MA), operated in negative electrospray 
ionization mode. Mass accuracy and reproducibility were maintained by using an 
independent reference spray by the LockSpray interference. The analytical column was a 
100mm x 2.1mm i.d., 1.7mm C8 Acquity UPLC BEH (Waters). The two mobile phases were 
A: methanol:water:formic acid (74:25:1); B: methanol:formic acid (99:1), both also contained 
5mM ammonium formate. A linear gradient was programmed as follows: 0.0 min: 80% B; 3 
min: 90% B; 6 min: 90% B; 15 min: 99% B; 18 min: 99% B; 20 min: 80% B. The flow rate was 
0.3ml/min. Positive identification of all sphingolipid species was based on the accurate mass 
measurement with an error <5 ppm and their LC retention time. 
 
2.6. Cell culture 
T. gondii (strain RH, TATi-1; a kind gift from Prof Dominique Soldati-Favre, University of 
Geneva) were maintained in Vero cells grown in DMEM supplemented with 10% foetal 
bovine serum (FBS) at 37C and 5% CO2. Parasites were separated from host cell material 
by filtration through 3 and 5 m polycarbonate filters (Millipore) after disruption by passage 
through a 26-gauge needle. Chinese Hamster Ovary (CHO-K1) cells, the derived 
temperature sensitive serine palmitoyl transferase mutant SPB-1, plus SPB-1 complemented 
with cLCB-1 [30] were grown in Ham’s F-12 media (Sigma-Aldrich) supplemented with 10% 
FBS (Gibco) at 37°C or 33°C (SPB-1 permissive temperature) with 5% CO2.  
 
2.7. Suppression of host sphingolipid synthesis 
For induction of the temperature-sensitive phenotype 105 cells were seeded into 24-well 
plates and incubated at 33°C for 24 hours. The medium was then replaced with Ham’s F12 
medium supplemented with 10% FBS or, to form serum reduced media, 0.1% FBS, 1% 
Nutridoma-SP (Roche Applied Science), 250 µM oleic acid (Sigma Aldrich) and 5% fatty acid 
free Bovine Serum Albumen (BSA; Sigma Aldrich). The low-serum medium contains less 
than 1µM sphingomyelin [31]. As indicated, myriocin (Sigma Aldrich) was added at this 
stage. Cells were then incubated at 39°C for 72 hours before T. gondii, purified as above, 
were added at a ratio of 2 parasites to 1 host cell and allowed to invade for 4 hours. 
Subsequently, after washing with PBS, cells were incubated for a further 24 hours in normal 
or serum reduced media before assay. Cell viability under these conditions was confirmed by 
staining with trypan blue (Sigma Aldrich). 
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2.8. Parasite invasion 
T. gondii infected cells were fixed with methanol at -20°C for 10 minutes, dried and stained 
with 300nM DAPI in PBS for 5 minute. Visualisation on an Olympus 1X-71 epifluorescent 
microscope allowed invasion to be scored. 
 
2.9. Parasite proliferation  
Following the four hour invasion time, 1.0µCi of [5,6-3H] uracil (GE Healthcare) was added 
per well and cultures incubated for 24 hours. Supernatant was removed and cells then 
solublised with 250µl of 1% (w/v) SDS containing 400µg of unlabelled uracil/ml. 750µl of 
0.3M TCA was then added and, after a 15 minute incubation at 4°C, precipitates were 
collected onto glass fibre filters in 96 well plates (Multiscreen HTS, Millipore) using a 
sampling manifold. The filters were washed twice with 0.3 M TCA and once with 95% 
ethanol, dried, placed in 10 ml of scintillation cocktail and the incorporated radioactivity then 
measured (Wallac 1450 MicroBeta TriLux, Perkin Elmer). 
 
 
3. Results and discussion 
 
3.1. Identification of the Toxoplasma gondii sphingolipid synthase 
Although T. gondii has been demonstrated to synthesize complex sphingolipids de novo [7, 
8], the identity of the enzymes responsible for this have remained unclear. However, it has 
been shown, by incorporation of tritiated inositol, that T. gondii tachyzoites synthesize the 
non-mammalian, complex phosphosphingolipid, inositol phosphorylceramide (IPC) [14]. In 
addition, the synthesis of glycosphingolipids and sphingomyelin (SM), the predominant 
mammalian phosphospingolipid, have been similarly demonstrated [7, 8]. Previous 
bioinformatic analyses have identified 2 orthologues of the mammalian SM synthase 
encoded by P. falciparum, PfSMS1 and 2 [12], an apicomplexan known to synthesize this 
sphingolipid species [9], and a single putative orthologue in the T. gondii genome [13]. This 
T. gondii predicted protein demonstrated only 28% and 27% identity to PfSMS1 and 2 
respectively. However, further analyses of the predicted amino acid sequence identified the 
canonical SM synthase domains (D1-4) [12] (figure 1), strongly suggesting that this predicted 
protein is evolutionarily and functionally related to this class of enzymes. Phylogenetic 
analyses using the Maximum Parsimony algorithm (PHYLIP Phylogeny Inference Package, 
version 3.5c), of aligned amino acid sequence (TgSLS amino acids 92-362) including the 
active site residues defined by D3 and D4, supported this hypothesis and indicated that the 
apicomplexan sphingolipid (SL) synthases form a new group in a wider enzyme family that 
includes both SM and IPC synthases (figure S1) [32]. However, further analyses using 
Maximum Likelihood and Protein Distance (PHYLIP) algorithms (data not shown) failed to 
support this result demonstrating the surprising divergence of TgSLS with respect to the 
other sphingolipid synthases, including PfSMS1 and 2.  
No functional analyses of these apicomplexan enzymes has previously been undertaken. 
Therefore, the open reading frame of the putative Toxoplasma SL synthase (TgSLS) was 
cloned into an URA3 selectable expression vector creating pRS426 TgSLS. Ectopic 
expression from this vector was subsequently demonstrated to restore the grow of YPH499-
HIS-GAL-AUR1, the previously constructed AUR1 auxotrophic mutant [27], in non-
permissive glucose containing media (figure 2). These data indicated that TgSLS is a 
functional orthologue of the yeast IPC synthase, AUR1p [33]. 
 
3.2. The functionality of the Toxoplasma gondii sphingolipid synthase  
Given the evidence that Toxoplasma synthesize SM [7], IPC [14] and, perhaps, CPE [13] it 
was necessary to ascertain the functionality of TgSLS. To this end, microsomes were 
prepared from YPH499-HIS-GAL-AUR1 pRS426 TgSLS and formatted into an in vitro assay 
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as previously described for other enzymes of this class [17, 18, 32]. The detergent wash in 
the preparation of the microsomes in this process removes lipids and therefore renders the 
enzyme largely dependent on the addition of exogenous substrate, the labelled acceptor 
substrate NBD-C6-ceramide and the donor substrate, phosphatidylinositol (for IPC synthesis) 
or phosphatidylcholine (for SM) [17]. TgSLS clearly synthesizes a product migrating with IPC 
on the addition of exogenous PI, but no evidence for the utilisation of PC for SM synthesis or 
phosphatidylethanolamine (PE) for CPE synthesis was seen under the conditions employed 
(figure 3). The Toxoplasma enzyme clearly functions as an IPC synthase, an activity that is 
increased approximately 5-fold on the addition of the donor substrate PI to the assay (figure 
S2A). There was also a small increase in IPC signal on the addition of both PC and PE. This 
small effect was consistent across four repeats and could be due to these lipids altering the 
composition of the micelles formed after the CHAPS wash, perhaps leading to increased 
availability of the remaining endogenous PI. In contrast, the yeast IPC synthase, AUR1p, is 
non-responsive to the mammalian PI employed in this assay system (figure S2B) [18]. 
 
3.3. Inositol phosphorylceramide in Toxoplasma gondii  
Lipidomic analyses have identified the presence of SM, CPE, but not IPC in Toxoplasma 
[13]. Therefore, in order to investigate whether the parasite harbours this non-mammalian 
sphingolipid species analyses by liquid chromatography-mass spectrometry (LC-MS) [34] of 
lipids extracted from isolated T. gondii and host Mouse Embryonic Fibroblast (MEF) cells 
were performed (figure 4). The unambiguous identification of IPC was achieved by accurate 
mass determination by high resolution Time-of-Flight (TOF) mass spectrometry. A selected 
negative ion UPLC-TOF chromatogram, corresponding to the deprotonated C16-IPC 
species, of the T. gondii lipid extract exhibited a peak absent in the mammalian host cells 
(figure 4A). In contrast, selected negative ions corresponding to the formic acid adduct of SM 
(figure 4B) and deprotonated CPE (figure 4C) were detected in both host and parasite 
extracts, with CPE appearing enriched in T. gondii as previously recorded [13]. The mass 
spectrum of these peaks (figure 4D) showed an accurate mass measurement with errors with 
respect to the theoretical spectra (figure 4E), of 0.3 ppm and 3.5 ppm for SM and CPE, and 
0.6 ppm for IPC. In addition, they demonstrated very similar isotopic patterns. These data 
demonstrate, for the first time, the presence of non-mammalian IPC (C18:1/C16:0) in T. 
gondii and strongly suggest that the IPC synthase activity of TgSLS seen in vitro above is 
also evident in vivo.  
 
3.4. Inositol phosphorylceramide synthase as a drug target in Toxoplasma gondii  
The, then uncharacterised, Toxoplasma IPC synthase activity has previously been proposed 
as a drug target based on the efficacy of the potent, well-characterized fungal IPC synthase 
inhibitor aureobasidin A (AbA) against T. gondii within infected host cells [14]. To test this 
hypothesis we chose to analyse the sensitivity of YPH499-HIS-GAL-AUR1 pRS426 TgSLS to 
AbA by diffusion assay (Figure 5A). AbA sensitive YPH499-HIS-GAL-AUR1 pRS426 AUR1 
was used as a positive control and the sphingolipid bypass mutant AGD as a negative 
control. AGD is able to grow without synthesizing sphingolipids and therefore is able to 
tolerate loss-of-function mutations in both serine palmitoyltransferase and IPC synthase [33]. 
These results demonstrated that TgSLS (the Toxoplasma IPC synthase) conferred AbA 
resistance to the yeast. The hyper-sensitivity to myriocin (an inhibitor of an upstream step in 
sphingolipid biosynthesis mediated by serine palmitoyltransferase) resembled that seen in 
the same mutant yeast complemented by the Leishmania major IPC synthase [28]. The 
reasons for this are unknown but perhaps reflect a sub-optimum functionality of the 
protozoan sphingolipid synthases in the yeast making the complemented lines more 
sensitive to upstream inhibition of sphingolipid biosynthesis.  
To further investigate any inhibition of Toxoplasma IPC synthase activity by AbA the 
microsomal assay described above was employed (figure 5B). Small, but statistically 
significant, inhibition of enzyme turnover was noted at 100 M. However, in contrast it should 
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be noted that the aureobasidin A is a tight binding inhibitor of the yeast IPC synthase 
(AUR1p) with a reported IC50 of 0.2 nM [33]. Together, these data demonstrate that TgSLS is 
largely resistant to AbA and, as such, resembles the characterized, AbA-resistant IPC 
synthase from the kinetoplastid protozoan parasite, Leishmania major [28]. 
Therefore, TgSLS is not the target for aureobasidin A in T. gondii and the previously reported 
efficacy [14] may be due to unidentified off target host effects as hypothesized for the 
kinetoplastid protozoa T. cruzi [35]. 
 
3.5. The role of host sphingolipid biosynthesis in Toxoplasma gondii proliferation 
As demonstrated above and previously [7] T. gondii have the ability to synthesize 
sphingolipids de novo. However, as an intracellular parasite T. gondii may also utilise host 
sphingolipids. In order to unravel the roles of host synthesis in parasite proliferation, Chinese 
Hamster Ovary (CHO) cells with a temperature sensitive serine palmitoyltransferase (SPT) 
were utilised as host cells [30, 31]. SPT is the first and rate-limiting enzyme in eukaryotic 
sphingolipid biosynthesis and in this cell line, SPB-1, the LCB1 subunit of this heterodimeric 
enzyme is thermolabile. At the non-permissive temperature virtually no SPT activity is 
detectable and sphingolipids are depleted when the SPB-1 cells are grown with minimal sera 
[36]. This phenotype is reversed by stable transfection of cDNA encoding cLCB1 [36]. Like T. 
gondii, the bacterial pathogen Chlamydia trachomatis (the causative agent of trachoma) 
resides within a non-fusagenic inclusion. Within SPB-1 cells C. trachomatis are completely 
unable to replicate at the non-permissive temperature, demonstrating that host sphingolipid 
biosynthesis is essential for intracellular growth of this pathogen [37] which acquires newly 
synthesized SM via the host exocytic pathway [38-41]. 
Utilising the same conditions employed in study of C. trachomatis replication [37], the 
proliferation of T. gondii in SPB-1 CHO cells was investigated. Briefly, before invasion host 
cells (both SPB-1 and controls) were incubated for 72 hours at the non-permissive 
temperature (39C) in either complete or serum-reduced media. In the same media the cells 
were infected with isolated T. gondii as described in Materials and Methods, and proliferation 
established by measuring [3H]-uracil incorporation as previously described [42] (figure 6A 
and B). It was clear that under the non-permissive conditions but in complete media the 
parasites replicated as well in the SPT deficient SPB-1 cells as they did in the wild type 
parental line (figure 6A). In contrast, with serum-reduced media T. gondii proliferation in the 
ts mutant cells was significantly reduced compared with the wild type control (p<0.001; figure 
6B). Notably, this effect was rescued in SPB-1 cells complemented by the expression LCB1 
from stably transfected cDNA. Furthermore, these results are not due to differential T. gondii 
invasion as, under these conditions, there was no significant difference (p>0.1) in the 
invasion rate between any of the cell lines employed (figure 6C). SPT can also be specifically 
inhibited by the natural product sphingosine analogue, myriocin [43]. Importantly, this 
induced a similar decrease in T. gondii proliferation in wild type CHO cells to that seen in the 
SPB-1 mutant. No effect was observed on treatment of the SPB-1 cells in which SPT activity 
was already suppressed, indicating that the effect seen in wild type cells was due to inhibition 
of host SPT and not the uncharacterised parasite orthologue (Figure 6D). This may be due to 
the Toxoplasma SPT being either resistant or inaccessible to myriocin. Alternatively 
modulation of parasite SPT activity may have only a limited effect on proliferation. However, 
clearly whilst host sphingolipid biosynthesis clearly plays a role in parasite replication, unlike 
for the bacterium C. trachomatis [37], it is non-essential. Furthermore, the addition of serum 
to the media negated any effect, indicating that scavenging from the extracellular milieu can 
compensate for the lack of host SPT activity. Notably, previous studies of T. gondii 
development within enucleated cells did not record any significant differences in parasite 
growth compared to nucleated controls [44]. Taken together these results indicate that host 
synthesis is not immediately critical for the ability of the parasite to grow, although prolonged 
depletion of sphingolipids (both synthesized and exogenous for 96 hours) does influence 
proliferation (an approximate 40% reduction). This contrasts with the intra-cellular 
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kinetoplastid, protozoan parasite Leishmania mexicana where suppression of host 
sphingolipid synthesis and depletion of extracellular lipid showed no effect on parasite 
proliferation [45]. 
 
 
4. Conclusion 
 
T. gondii is an important cause of disease in humans and domestic animals and a model 
apicomplexan pathogen [46]. The essential, eukaryotic sphingolipids have been implicated in 
the interaction of the related apicomplexan P. falciparum with its anucleate host cell, the 
erythrocyte [6]. In this study we utilised the ability of T. gondii to invade and colonize a wide 
range of nucleated vertebrate cells to examine the role host sphingolipid synthesis in 
invasion and proliferation. Genetic and chemical inhibition of the host pathway, coupled with 
depletion of media lipid, inhibited parasite proliferation (but not invasion). However, in 
contrast to the bacterium C. trachomatis [37], T. gondii was still able to replicate under these 
conditions. Notably, while auxotrophic for sterols [24], T. gondii have maintained the ability to 
synthesize sphingolipids de novo [7]. It could be hypothesised that this allows the parasite to 
survive and replicate in conditions of greatly reduced host sphingolipid biosynthesis. 
However, the protozoan biosynthetic pathway and the identity of the enzymes that constitute 
it remained relatively uninvestigated. In this study we showed that the identified T. gondii SL 
synthase demonstrated IPC synthase activity in vitro, and that this non-mammalian lipid 
species is detectable by mass spectrometry in parasite extracts. Given the status of the 
fungal AUR1p and kinetoplastid IPC synthases as promising drug targets [3], the 
identification of the T. gondii orthologue opens up the possibility of targeting this enzyme with 
novel anti-protozoals. However, the ability of the parasite to scavenge sphingolipid from the 
host may complicate the viability of TgSLS as a pharmaceutical target and clearly the 
balance between de novo synthesis and scavenging merits further investigation. 
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Figure Legends 
 
Figure 1. Identification of a candidate sphingolipid synthase from Toxoplasma gondii 
(TgSLS). Protein sequence alignment of D1, D2, D3 and D4 from HsSMS1 and 2, PfSMS1 
and 2 and TgSLS. The positions highlighted in black are fully conserved; those in dark grey 
show conservation of strongly similar groups; those in light grey show conservation of weakly 
similar groups. The 3 residues of the predicted catalytic triad within D3 and D4 are 
designated by *. 
 
 
 
Figure 2. TgSLS complements a yeast AUR1p auxotrophic mutant. The growth of YPH499 
HIS-GAL-AUR1 transformed with pRS426 TgSLS, a positive control (pRS426 ScAUR1) and 
a negative control (empty pRS426, pRS) was supported on permissive SGR media 
(galactose as carbon source). In contrast, only pRS426 TgSLS and the positive control could 
grow on non-permissive SD media (glucose as carbon source). 
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Figure 3. TgSLS functions as an inositol phosphorylceramide synthase. HPTLC fractionation 
of lipids after reaction of CHAPS-washed TgSLS extract with acceptor substrate NBD-C6-
ceramide and either no donor substrate (-) or phosphatidylinositol (PI), 
phosphatidylethanolamine (PE) or phosphatidylcholine (PC). Only the addition of PI led to a 
significant increase in the product formation, a species migrating with inositol 
phosphorylceramide (IPC). A representative image, O was the origin, ceramide (Cer) 
migrated at the front, markers from extracts of NBD-C6-ceramide labeled yeast (NBD-IPC) 
and mammalian Vero cells (NBD-SM). 
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Figure 4. Inositol phosphorylceramide identification in Toxoplasma gondii lipid extracts. (A) 
Selected negative ion m/z 778.5234 (inositol phosphorylceramide, N-hexadecanoyl (N-C16) 
species, IPC); (B) selected negative ion m/z 747.5652 (sphingomyelin, N-hexadecanoyl (N-
C16) species, SM); and (C) selected negative ion m/z 659.5128 (ceramide 
phosphorylethanolamine, N-hexadecanoyl (N-C16) species, CPE) UPLC-TOF 
chromatograms of Mouse Embryonic Fibroblast (MEF) host cells and T. gondii lipid extracts. 
(D) Partial mass spectra (from 590 to 850 amu) corresponding to the 6 and 7.8 min range of 
a representative chromatogram obtained by UPLC/TOF-ESI(-) analysis of lipid extracts of  
host cells and T. gondii. Regions amplified (x20 or x30) as indicated. (E) Theoretical mass 
spectral pattern for the molecular ion region showing an (M-H)- ion for CPE and IPC and 
(M+HCOO-) for SM. CPE and SM were found in both samples, whereas IPC was only 
identified in T. gondii extracts.   
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Figure 5. TgSLS sensitivity to a verified yeast AUR1p inhibitor. (A) Agar diffusion assay of 
YPH499 HIS-GAL-AUR1 complemented yeast showed that, as expected, ScAUR1 
complemented yeast were sensitive to myriocin at 1mM (Myr) and aureobasidin A at 25µM 
(AbA25). In contrast, TgSLS complemented yeast were resistant to AbA at 25µM and 100µM 
(AbA100), but hyper-sensitive to myriocin (1mM) as evidenced by large zones of exclusion. 
AGD, the sphingolipid bypass mutant yeast lacking functional SPT and AUR1, acted as the 
negative control. DMSO was the vehicle control; (B) In vitro assay of the inhibitory effect of 
aureobasidin A (AbA) on TgSLS demonstrated that the Toxoplasma enzyme is only 
marginally, but significantly (p<0.01), sensitive to the drug at a high concentration (100µM). 
Fluorescence intensity of IPC was established following fractionation by HPTLC and 
normalised with respect to an untreated control. Mean of 3 independent experiments, 
standard deviation indicated. 
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Figure 6. Analyses of the role of host serine palmitoyltransferase (SPT) in Toxoplasma 
gondii proliferation and invasion. Cells were cultured in 10% FCS (A) or in serum-reduced 
media (B) at the non-permissive temperature (39C). In the presence of complete media, T. 
gondii proliferation was the same in wild type (CHO-K1) and SPT-compromised (SPB-1) host 
cells (A). However, in serum-reduced media proliferation was significantly (p<0.001) 
decreased in SPB-1 cells compared to the control (CHO-K1 and SPB-1 cLCB1) lines (B). All 
results normalised with respect to proliferation in parental CHO-K1 cells. Analyses of 3 
independent experiments performed in triplicate, standard deviation indicated. This effect 
was not due to significant differential invasion of the host cell lines (p>0.1; C). Analyses of 3 
independent experiments, standard deviation indicated. To analyse the effect of chemical 
inhibition of SPT, cells were cultured in serum-reduced media at the non-permissive 
temperature (39C) in the presence or absence of the inhibitor, myriocin (D). Myriocin 
treatment reduced Toxoplasma proliferation (p<0.05) in wild type (CHO-K1) cells to similar 
levels to those seen in untreated SPT-compromised (SPB-1) host cells. The compound had 
no effect on proliferation in SPB-1 cells but exerted a similar effect to wild type in 
complemented mutant cells (SPB-cLCB1; p<0.05). All results normalised with respect to 
proliferation in parental CHO-K1 cells. Analyses of experiments performed in triplicate, 
standard deviation indicated. 
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Supplementary Figure 1. Maximum parsimony analyses of Animalae, Fungi, 
Trypanosomatidae, Plantae and Apicomplexa sphingolipid synthase predicted amino acid 
sequences. Bootstrap scores >60 indicated. Homo sapiens LPP1 (outgroup) accession 
number: O14494; T. gondii SLS: 50.m03113; P. falciparum SMS1&2: PFF1210w and 
PFF1215w; Arabidopsis thaliana IPCS1-3: At3g54020.1, At2g37940.1, At2g29525.1; T. 
brucei SLS1-4: Tb09.211.1030, Tb09.211.1020, Tb09.211.1010, Tb09.211.1000; T. cruzi 
IPCS1&2: Tc00.1047053506885.124, Tc00.1047053510729.290; L. major IPCS: 
LmjF35.4990; Aspergillus fumigatus AUR1p: AAD22750; Candida albicans AUR1p: 
AAB67233; Pneumocystis carinii AUR1p: CAH17867; Saccharomyces cerevisiae AUR1p: 
NP_012922; Schizosaccharomyces pombe AUR1p: Q10142; Caenorhabditis elegans SMS1-
3: Q9U3D4, AAA82341, AAK84597; Homo sapiens SMS1&2: AB154421, Q8NHU3; Mus 
musculus SMS1&2: Q8VCQ6, Q9D4B1. 
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Supplementary Figure 2. (A) In vitro assay of TgSLS with no donor substrate (-) or PI 
demonstrated that IPC synthase activity was increased approximately 5-fold in the presence 
of this donor substrate; (B) In contrast, in an equivalent assay ScAUR1 was non-responsive 
with the bovine PI utilized. AFU – Arbitrary Fluorescence Units). Mean of 3 independent 
experiments, standard deviation indicated. 
 
